Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8NHY0
UPID:
B4GN2_HUMAN
Alternative names:
Sd(a) beta-1,4-GalNAc transferase; UDP-GalNAc:Neu5Aca2-3Galb-R b1,4-N-acetylgalactosaminyltransferase
Alternative UPACC:
Q8NHY0; B4DZE4; Q14CP1; Q86Y40
Background:
Beta-1,4 N-acetylgalactosaminyltransferase 2, also known as Sd(a) beta-1,4-GalNAc transferase, plays a crucial role in synthesizing the Sd(a) antigen. This antigen is a carbohydrate determinant found on erythrocytes, colonic mucosa, and other tissues, involving the transfer of a beta-1,4-linked GalNAc to the galactose residue of an alpha-2,3-sialylated chain.
Therapeutic significance:
The protein's involvement in Sd(a) polyagglutination syndrome, a condition marked by red blood cells agglutination, highlights its potential as a target for therapeutic intervention. Understanding the role of Beta-1,4 N-acetylgalactosaminyltransferase 2 could open doors to potential therapeutic strategies.